Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Significant Accounting Policies (Details Narrative)

v3.24.2.u1
Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
May 15, 2024
Feb. 21, 2019
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2022
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Apr. 19, 2024
Loss on deconsolidation of foreign subsidiaries     $ 122,600   $ 220,272 $ 1,564,823  
Purchase price of license fair value           75,000    
FDIC insured amount     250,000     250,000      
Cash uninsured amount     $ 127,434     $ 127,434      
Exercise price per share     $ 0.18     $ 0.18      
Prefunded Warrant [Member]                  
Prefunded warrant                 8,666,667
Common Stock [Member]                  
Exercise price per share                 $ 0.00001
Petalo Pharmaceutical, S.A.S [Member]                  
Purchase price of license fair value $ 75,000                
Merger Agreement [Member]                  
Share based payment award shares purchased   825,000              
Share price   $ 0.50              
Merger Agreement [Member] | OWP Ventures, Inc. [Member]                  
Business acquisition, equity interest issued or issuable, number of shares   39,475,398              
Share based payment award shares purchased   825,000              
Share price   $ 0.50              
Proceeds from convertible debt   $ 300,000              
Conversion price   $ 0.424              
Common stock shares cancelled   875,000              
Payments for custom clearance         $ 1,400,000